Issue |
Vet. Res.
Volume 38, Number 1, January-February 2007
|
|
---|---|---|
Page(s) | 1 - 14 | |
DOI | https://doi.org/10.1051/vetres:2006040 | |
Published online | 01 November 2006 | |
How to cite this article | Vet. Res. (2007) 1-14 |
DOI: 10.1051/vetres:2006040
Immunostimulatory properties of a novel adjuvant administered with inactivated influenza virus vaccine
Vincent Wellemans, Sylvette Laurent, Pierre Hélie and Youssef ElAzharyFaculté de médecine vétérinaire, Université de Montréal, PO Box 5000, Saint-Hyacinthe, Qc, J2S 7C6, Canada
(Received 27 November 2005; accepted 12 June 2006; published online 1 November 2006)
Abstract - The immunopotentiating activity of a new delivery system was investigated
comparatively to Alhydrogel
adjuvant, as an
antiviral inactivated vaccine after one injection. The efficiency of the new
formulation (BioMed) was evaluated with an inactivated porcine strain of
influenza (A/Sw/IN/1726/88 H1N1) in the pig model. The first assessment
criteria was the follow-up of selected immunological parameters such as,
antibody levels, lymphoproliferation, double positive CD4+CD8+ T
lymphocytes and cytokine production (IL-2, IL-4, IFN-
. The second
criteria was the estimate of the protection level of animals exposed to a
homologous challenge of 50 PID50 one month after a single immunizing or
control injection. In the BioMed group of animals, 4 pigs (out of 6) were
free of macroscopic lesion, while lesions could be seen in all individuals
of other groups and virus was isolated in only one animal, whereas all other
animals of other groups had virus in their lungs. This better protection of
BioMed animals seems to be correlated mainly with higher levels of
antibodies and to a lesser extent with a slightly better CMI response and
probably with the production of memory CD4+CD8+ T cells.
Key words: H1N1 swine influenza virus / immunopotentiating adjuvant / inactivated vaccines
Corresponding author: sylvette.laurent-lewandowski@umontreal.ca
© INRA, EDP Sciences 2007